Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Up-gone?

Executive Summary

Pharmacia Corporation will be the name of the company created through the merger of Pharmacia & Upjohn and Monsanto. The combined company's autonomous agricultural subsidiary will retain the name Monsanto, while the Searle, Upjohn and Pharmacia names will be used to designate sales divisions. The Pharmacia name will be used in combination with the color and typeface of the current Searle logo (1"The Pink Sheet" Jan. 3, p. 3)

You may also be interested in...



Monsanto/P&U Aggregation Hinges On Ag Business: Pull Of Pooling?

Monsanto's proposed merger of equals with Pharmacia & Upjohn hinges upon convincing shareholders that there is value in delaying the unlocking of Monsanto's ag business from the Searle pharmaceutical business.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel